These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 20385331)

  • 41. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis.
    Giuliani F; Fu SA; Metz LM; Yong VW
    J Neuroimmunol; 2005 Aug; 165(1-2):83-91. PubMed ID: 15958276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
    Ouallet JC
    Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 44. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.
    Legha SS; Buzaid AC
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):27-32. PubMed ID: 8054006
    [No Abstract]   [Full Text] [Related]  

  • 45. Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.
    Antel JP; Miron VE
    Clin Neurol Neurosurg; 2008 Nov; 110(9):951-7. PubMed ID: 18502570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic role of beta-interferons in multiple sclerosis.
    Javed A; Reder AT
    Pharmacol Ther; 2006 Apr; 110(1):35-56. PubMed ID: 16229894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Oral therapy for multiple sclerosis!].
    de Seze J
    Rev Neurol (Paris); 2010 Apr; 166(4):363-4. PubMed ID: 20385331
    [No Abstract]   [Full Text] [Related]  

  • 48. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
    Wiendl H; Hohlfeld R
    Neurology; 2009 Mar; 72(11):1008-15. PubMed ID: 19289741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of interferon-beta treatment on the blood-brain barrier.
    Kraus J; Oschmann P
    Drug Discov Today; 2006 Aug; 11(15-16):755-62. PubMed ID: 16846804
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.